这项研究旨在探讨AR在HER2+非转移性乳腺浸润性导管癌（IDC）中的预后价值以及其与免疫微环境的关系。包括2016年至2017年在中山大学肿瘤防治中心接受手术的经病理学诊断的HER2+非转移性乳腺癌IDC患者。为进行免疫浸润分析，匹配年龄、T期和N期的AR+和AR-乳腺癌IDC样本1:1。本回顾性研究共纳入554例HER2+非转移性乳腺癌患者，不考虑HR状态。 AR的截断值设置为10％。 ER+（P＜0.001）和PR+（P＜0.001）与阳性的AR表达有关。 Kaplan-Meier生存曲线分析表明，AR与总生存期（OS）密切相关（P=0.001），但与无病生存期（DFS）无显著关联（P=0.051）。排除HR的潜在影响后，AR也预测了更长的OS（P=0.014），并是HER2+HR-非转移性乳腺癌IDC患者OS的独立预测因素，多变量分析揭示（P=0.036）。对于配对的AR+和AR- HER2+HR-患者，TILs（P=0.043）和PD-L1（P=0.027）水平在AR+患者中显著降低。 AR和PD-L1之间观察到最强的负相关（Pearson的r=-0.299，P=0.001）。 AR+状态明显与HER2+HR-非转移性乳腺癌患者更好的OS相关，在AR和PD-L1 / TILs之间观察到负相关。我们提供了AR预后价值及其与免疫微环境相关性的新见解，以优化HER2+非转移性乳腺癌IDCs的治疗策略。©2023年作者（们）。

This study aimed to investigate the prognostic value of AR in HER2+ nonmetastatic breast invasive ductal carcinoma (IDC) and its relationship with the immune microenvironment. HER2+ nonmetastatic breast IDC patients diagnosed by pathology who underwent surgery at Sun Yat-sen University Cancer Center from 2016 to 2017 were included. AR+ and AR- breast IDC samples were matched 1:1 in age, T stage, and N stage for immune infiltration analysis. A total of 554 patients with HER2+ nonmetastatic breast cancer were included in this retrospective study, regardless of HR status. The cut-off value for AR was set at 10%. ER+ (p < 0.001) and PR+ (p < 0.001) were associated with positive AR expression. Kaplan-Meier survival curve analysis suggested that AR was closely correlated with overall survival (OS) (p = 0.001) but not disease-free survival (DFS) (p = 0.051). After eliminating the potential impact caused by HR, AR also predicted longer OS (p = 0.014) and was an independent predictive factor for OS of HER2+HR- nonmetastatic breast IDC patients, as revealed by multivariate analysis (p = 0.036). For AR+ and AR- matched HER2+HR- patients, TILs (p = 0.043) and PD-L1 (p = 0.027) levels were significantly lower in AR+ patients. The strongest negative correlation was observed between AR and PD-L1 (Pearson's r = -0.299, p = 0.001). AR+ status was markedly related to better OS in HER2+HR- nonmetastatic breast cancer patients, while a negative correlation was observed between AR and PD-L1/TILs. We provide new insights into the prognostic value of AR and its association with the immune microenvironment to optimize treatment strategies in HER2+ nonmetastatic breast IDCs.© 2023. The Author(s).